Videos

The director of the University of Rochester Alzheimer's Disease Care, Research and Education Program spoke about the need to rethink trial design and Alzheimer neuropsychiatric symptom management.

This is the first large late-stage clinical trial to further support the amyloid hypothesis.

The SPRINT MIND trial found a statistically significant lower rate of new cases of mild cognitive impairment in the intensive treatment group.

The psychiatry and pharmacology professor spoke about the results from the first clinical trial that showed that a cannabinoid can decrease agitation in Alzheimer disease.

Efficacy was demonstrated in this patient population at the primary endpoint of 6 weeks, especially in those with more severe baseline NPI-NH-PS.

Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.

These guidelines will provide primary clinicians and the specialist community an important new tool to more accurately diagnose patients.

A prospective cohort study of patients offered amyloid PET as part of their dementia work-up. The results here.

The FDA has approved a new drug for the prevention of migraines. Will the injectable treatment help reduce the number of days of migraine headaches?

How effective is the telemedicine versus telephonic approach in acute care?

An update on the prevalence and features of demoralization in patients with PD.

5 key facts about cerebral microbleeds and risk of future cognitive impairment.

5 important facts from a recent double-blind, randomized phase 3 study about siponimod in SPMS.

The group medical director of neuroscience at Genentech discussed the history of a well-known therapy for multiple sclerosis: ocrelizumab (Ocrevus).

The associate professor of clinical neurology spoke about the need to understand modifiable social and cultural factors that could impact disease severity and progression.

The clinical director of the Anti-NMDA Receptor Encephalitis Foundation spoke about the insidiousness of AD and the need for diagnosis earlier in disease progression.

The UC Health professor of neurology argued that with the current view on Parkinson disease, the field is missing the mark for disease-modifying interventions.

The chief medical officer and chief operating officer of Brainstorm Cell Therapeutics spoke about a host of topics related to the treatment of amyotrophic lateral sclerosis.

A study examines a possible link between lifestyle and onset of PD.

Here: the most notable changes in the new AAN guideline on mild cognitive impairment.

A study looked at changes in retinal signs with fundus photography and their association with cognitive decline.

5 key facts about the association between cerebral microbleeds and risk of future intracerebral hemorrhage in patients with afib who take oral anticoagulants after ischemic stroke.

A large retrospective cohort study of over 12,000 patients from 40 hospitals looked at the risk of death following stroke or TIA, and whether patients had been prescribed antihypertensive medications.

A large study evaluated exercise and its effects on cognitive function in patients with, or at risk for, Alzheimer disease.

Lower serum caffeine levels may be of diagnostic significance in early Parkinson disease, consistent with epidemiologic data that support the neuro-protective properties of caffeine.

In this 6-minute video presentation, Dr. Andrew Wilner describes the epidemiology and pathophysiology of carbon monoxide poisoning and reviews the implications of a recently published observational study.

Although rare, new onset refractory status epilepticus can be life threatening if not identified quickly.

Findings from a study lends credence to the role of lipids in the early stages of Alzheimer disease.

An incident, population-based prospective cohort study examined weight changes over time in patients with Parkinson disease.

Researchers conducted a retrospective analysis of patients with acute stroke and evaluated the effect of infection during the hospitalization period.